Main Industry
Biotechnology
Main Product/Service
The primary focus is the development of a simple and cost-effective *Escherichia coli* (*E. coli*) expression system to produce grouper nervous necrosis virus (NNV) coat protein and immunostimulant protein, which serve as an in vitro immunostimulant for the prevention of viral nervous necrosis (VNN).
The content above was translated by Ai
Founded Year
2024
Unified Business No.
95451882
Status
Active
Number of Employees
0
Total Paid-in
Capital
30,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Yeti Tech Inc. was founded by students from the Department of Veterinary Medicine at National Taiwan University. Its team has developed a protein immunostimulant targeting nervous necrosis virus, aiming to reduce aquaculture costs and improve immunization efficiency. Upholding the vision of “Self-healing Health, Restoring Life,” the company integrates biotechnology innovation and medical care values, aspiring to build precise and decentralized medical tools.
The content above was translated by Ai
